Onxeo S.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
15,320.30
7,698.60
19,409.00
22,671.00
59,071.00
9,399
Depreciation, Depletion & Amortization
3.40
842.10
2,207.00
1,606.00
1,796.00
9,175
Other Funds
14.80
14,208.20
510.00
-
353.00
3,732
Funds from Operations
15,076.20
5,897.40
20,092.00
20,817.00
25,774.00
5,720
Changes in Working Capital
1,055.90
1,825.50
3,042.00
3,208.00
2,507.00
5,546
Net Operating Cash Flow
14,020.30
7,722.90
23,134.00
17,609.00
28,281.00
11,266
Capital Expenditures
58.30
2.00
410.00
545.00
65.00
Sale of Fixed Assets & Businesses
12.50
-
160.00
-
-
Purchase/Sale of Investments
3.00
1.60
15.00
12.00
2.00
Net Investing Cash Flow
42.70
0.30
235.00
1,849.00
67.00
Issuance/Reduction of Debt, Net
158.60
2,207.50
519.00
213.00
154.00
Net Financing Cash Flow
10,840.50
53,643.10
71.00
11,968.00
13,437.00
Net Change in Cash
3,174.10
45,897.90
23,434.00
4,549.00
14,966.00
Free Cash Flow
14,078.60
7,724.90
23,544.00
18,154.00
28,320.00
Deferred Taxes & Investment Tax Credit
-
-
-
-
7,801.00
1,764
Other Sources
-
-
-
2,406.00
-
Change in Capital Stock
10,667.00
37,227.50
80.00
12,181.00
13,944.00
Exchange Rate Effect
48.50
22.00
136.00
757.00
55.00

About Onxeo

View Profile
Address
49, blvd. du Général Martial Valin
Paris Ile-de-France 75015
France
Employees -
Website http://www.onxeo.com
Updated 07/08/2019
Onxeo SA is a biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. It produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA. The company was founded by Gilles Avenard and Dominique Costantini on March 5, 1997 and is headquartered in Paris, France.